Drug intelligence / Profile preview

Acufol

Development stage: Unknown
Lead developer: Acure Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Acufol** is an oral fixed-dose nutritional formulation developed and manufactured by Acure Pharma. It combines bioactive L-methylfolate, vitamin B12, and pyridoxal 5-phosphate to supplement folate, cobalamin, and vitamin B6 status and support one-carbon metabolism, methylation reactions, and homocysteine metabolism. It is marketed for nutritional supplementation, including management or prevention of folate-related nutritional deficiency. ([acurepharma.in](https://acurepharma.in/))

Brand names: Acufol
Other names: L-Methyl Folate with Vitamin B12 and Pyridoxine 5-Phosphate Tablets

Beyond the preview

Go deeper on Acufol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acufol.

Explore the full profile